Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …

Human leukocyte antigen (HLA) can recognize and bind foreign peptides to present them to
specialized immune cells, then initiate an immune response. Computational prediction of the …

Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

Discovery and development of biopeptides are time‐consuming, laborious, and dependent
on various factors. Data‐driven computational methods, especially machine learning (ML) …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

The broad application of precision cancer immunotherapies is limited by the number of
validated neoepitopes that are common among patients or tumor types. To expand the …

Neoantigen vaccines are based on epitopes of antigenic parts of mutant proteins expressed
in cancer cells. These highly immunogenic antigens may trigger the immune system to …

The success of protein engineering and design has extensively expanded the protein space,
which presents a promising strategy for creating next-generation proteins of diverse …

Abstract DNA N4-methylcytosine (4mC) is an important epigenetic modification that plays a
vital role in regulating DNA replication and expression. However, it is challenging to detect …